Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Breast Neoplasms 6Neoplasm Metastasis 5Neoplasms 4Triple Negative Breast Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia 1Hematologic Neoplasms 1Hemangiosarcoma 1Gastrointestinal Stromal Tumors 1

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × STA 9090 × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02637375 2016-05-30

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

University of Chicago

Phase NA Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01677455 2015-11-05

Enchant

Synta Pharmaceuticals Corp.

Phase 2 Completed
51 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡